Telviran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telviran

Quick Facts

Property Description
Active ingredient Aciclovir (INN)
Form Tablets, capsules, suspension, topical cream/ointment, solution for IV
Pharmacological class Antiviral, Purine Nucleoside Analogue
Common use Control of herpesvirus family infections
Origin Synthetic

The Core Identity: A Specialized Antiviral Drug

Telviran is a commercial brand name for the generic active substance Aciclovir (Acyclovir), a medicine officially classified as a highly selective antiviral medication. This drug is firmly categorized as a synthetic nucleoside analogue, confirming its identity as a chemically manufactured compound designed to combat specific viral pathogens. As a foundational therapy for certain viral infections, Aciclovir is included on the World Health Organization's List of Essential Medicines, underscoring its established importance in public health management.

Composition and Form: Synthetic Guanosine Analogue

Telviran's active ingredient is the synthetic compound Aciclovir, which is chemically derived to function as an analogue of the natural human nucleoside guanosine. This structural resemblance is essential to its mechanism of action. The compound is prepared in various pharmaceutical preparations to ensure optimal delivery: this includes oral options such as tablets and capsules for systemic treatment, and localized forms like topical creams and ointments for application directly to affected areas. The availability of both systemic and localized preparations provides versatility in managing different manifestations of the infection.

Functional Principle: Selective Viral Growth Disruption

Aciclovir's functional effectiveness relies on its high degree of specificity, which targets only the cells infected by the virus. The medication remains inert until a viral enzyme activates it within the infected cell, transforming it into its potent, active form. This activated compound then acts to halt viral DNA replication by incorporating itself into the growing viral genetic chain. This interference with the virus’s ability to multiply is the foundational mechanism that limits the infection's spread and controls the severity of the associated outbreak.

Regulatory References

  1. World Health Organization's List of Essential Medicines
  2. MedlinePlus: Acyclovir
  3. NIH: Acyclovir Mechanism of Action

What side effects are possible with Telviran?

Possible Side Effects and Safety Information

Official regulatory documents detail the known side effects and safety profile of Telviran (acyclovir), organizing them by frequency and the body system affected. All patients should maintain adequate hydration, as advised in regulatory labeling.

Serious and Clinically Significant Adverse Reactions

  • Renal Failure: Cases of kidney failure, which may be fatal, have been reported, particularly with intravenous use. This risk necessitates caution and dosage modification in patients with pre-existing renal impairment.
  • Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS): This potentially fatal condition, characterized by low red blood cells and platelets, has been reported in patients with impaired immune function.
  • Central Nervous System (CNS) Effects: Serious reactions include seizure, coma, hallucinations, confusion, and encephalopathy. These are noted to be more likely in older adults and those with renal impairment.
  • Hypersensitivity: Anaphylaxis and severe skin reactions, such as Stevens-Johnson syndrome, have been documented.

Common Adverse Reactions

Adverse effects commonly reported in clinical trials and practice, categorized by body system, include:

System-Organ Class Common Adverse Reactions
Nervous System Headache, dizziness, agitation
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain
Skin Rash, itching, photosensitivity
Other Fatigue, fever, pain

Safety-Related Restrictions and Considerations

  • Contraindication: This medicine is contraindicated for individuals with known hypersensitivity to Telviran or valacyclovir.
  • Special Populations: Dose adjustment is officially recommended for patients with reduced renal function and is frequently required for geriatric patients due to age-related changes in kidney function.
  • Drug Interactions: Caution is advised when co-administering this medicine with other agents known to be nephro-toxic (damaging to the kidneys), as this combination may increase the risk of renal or CNS adverse effects.

Overdose and Emergency Response

When to Seek Immediate Medical Help

Overdose of Telviran (telmisartan) is a serious medical event. Since the primary effect of the medication is to lower blood pressure, the most likely and significant risk of an overdose is severely low blood pressure (symptomatic hypotension).

Seek immediate emergency medical attention if you or someone else has taken more than the prescribed amount of Telviran. Even if symptoms are not yet present, medical professionals should be notified and monitoring should begin promptly.

Overdose Manifestations

Based on regulatory documents, the most common clinical manifestations expected following a Telviran overdose are related to its effect on the cardiovascular system:

  • Severe Hypotension: An extreme drop in blood pressure, which may lead to dizziness or fainting.
  • Heart Rate Changes: Both an abnormally fast heartbeat (tachycardia) and an abnormally slow heartbeat (bradycardia) may occur.

Required Emergency Actions

The treatment for an overdose of Telviran is primarily symptomatic and supportive. Medical monitoring will focus on stabilizing blood pressure and managing heart rate. The official instructions note that Telviran is not removed from the body by haemodialysis, meaning this procedure is not effective for drug removal in an overdose situation. Close monitoring and supportive care are essential until symptoms resolve.

Therapeutic Uses of Telviran

What Telviran Treats: Main Uses and Benefits

Telviran is generally used across conditions presenting with acute or disruptive episodes of Herpes Simplex Virus (HSV) manifestations, including genital herpes and herpes labialis (cold sores). The medication is applied to ease symptoms related to physical discomfort, specifically the clustered blisters and sores, as well as the initial tingling or burning sensations. The medicine is relevant in contexts marked by increased discomfort or tension associated with manifestations of the herpesvirus family, specifically Herpes Zoster (shingles). The drug is applied to ease symptoms of increased neurological or muscular activity and contributes to easing the overall symptom load of the rash.

“The medication contributes to improved comfort during periods of heightened symptoms and supports patients during episodes of heightened discomfort.”

It is also commonly used across conditions involving recurrent or episodic manifestations, and may be part of symptomatic management to help address the potential for frequent symptomatic episodes. It is applied in settings where supportive symptom management is appropriate for severe, systemic infections and in contexts involving functional stability becomes affected.

Quick Fact: Relief for Key Symptom Domains
Primary Focus: Supports the management of painful lesions, blisters, and the initial prodromal discomfort (tingling/burning).
Secondary Focus: Applied in addressing the severity and duration of shingles-associated neuralgic pain.
Highest Benefit: Contributes to functional stability by addressing the potential for frequent recurrences and managing acute, severe systemic infections.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Telviran (Aciclovir) eligibility rules are strictly defined by regulatory authorities based on population safety and physiological status.

Populations with Absolute Restrictions

Category Regulatory Status
Contraindicated Patients with known hypersensitivity to the active substance Aciclovir, its prodrug Valaciclovir, or any component of the specific formulation.
Not Recommended Patients with specific rare hereditary metabolic disorders (e.g., galactose intolerance) due to excipients in certain oral dosage forms.

Conditional and Age-Related Use

Age/Condition Eligibility Requirement
Impaired Renal Function Use is conditional and requires careful monitoring, as the medicine is cleared primarily by the kidneys.
Older Adults Use requires consideration of reduced renal function often associated with age; close monitoring is mandated.
Children/Infants Use and appropriate dose must be determined by a healthcare professional; the safety and effectiveness of oral formulations are often not established in children under 2 years of age.
Pregnancy/Lactation Use during pregnancy is restricted and must be considered only when the potential benefit outweighs the unknown risk. Caution is advised during breastfeeding, as the drug passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Telviran (Aciclovir) is structured around its renal elimination pathway, which dictates several documented pharmacokinetic and pharmacodynamic constraints.

Category Official Regulatory Statement
Exposure Modification Co-administration with Probenecid or Cimetidine increases Aciclovir plasma concentrations and reduces its renal clearance through competition for active renal tubular secretion. Similarly, co-administration with Mycophenolate Mofetil (MMF) results in increased exposure (AUC) of both Aciclovir and the inactive metabolite of MMF.
Pharmacodynamic Risk Caution is required during concurrent use with potentially nephrotoxic agents due to the officially documented increased risk of renal dysfunction. Antivirals, such as Zidovudine, have been associated with increased reports of fatigue upon combined use.
Food and Timing The official documentation confirms that Aciclovir absorption is not significantly affected by food, meaning no constraints are imposed regarding meal timing. Regulatory documents do not specify any mandatory timing separation rules for concurrent medications.
Population Consideration Elderly patients and individuals with renal impairment have an officially documented heightened risk of neurological side effects; this is a consequence of decreased drug clearance leading to elevated plasma exposure.

The regulatory profile documents that the clearance of Aciclovir and other medicinal products can be affected by the shared renal tubular secretion pathway. This pharmacokinetic domain establishes the need for consideration when combining Aciclovir with other drugs that compete for elimination, while other restrictions relate to the synergistic toxicological risk to kidney function.

Mechanism of Action

Telviran (Aciclovir) functions via a highly selective, multi-step molecular mechanism that interferes with the herpesvirus replication cycle.

Selective Antiviral Activation: The "Trojan Horse" Principle

The mechanism relies on the virus-encoded Viral Thymidine Kinase (TK) enzyme. This enzyme recognizes the inactive drug and initiates its conversion into the first active form, a process that occurs preferentially within virus-infected cells. This molecular selectivity results in the drug's action being preferentially concentrated within the replication machinery of the pathogen rather than in non-infected host cell pathways.

The DNA Chain Termination Cascade

Once activated, the drug is further metabolized into Aciclovir Triphosphate (ACV-TP), which directly targets the Viral DNA Polymerase. ACV-TP competes with natural building blocks of the viral genome, and upon insertion into the growing DNA strand, it functions as an obligate chain terminator. This irreversible action prevents the assembly of new viral DNA, causing the cessation of further viral genome synthesis.

Mechanistic Constraints: Latency and Resistance

This mechanism is engaged only when the virus is actively replicating (lytic phase), as it requires the presence of the Viral TK enzyme. The drug has no mechanism of action against the virus in its dormant state (latency). Furthermore, mutations in either the Viral TK or the Viral DNA Polymerase can compromise the mechanism, leading to reduced drug activation or affinity, which results in viral resistance.

Dosage and Administration Information

How Telviran Is Used: Official Administration Guidelines

Telviran, containing Aciclovir, is administered via three primary, officially approved routes: oral (using tablets, capsules, or suspension), intravenous (IV) infusion for systemic treatment, and topical for localized use. The selection of the route and dosage is strictly dependent on the administration context.

Dosing schedules are highly context-dependent. Acute treatment of infections typically requires short courses of therapy, utilizing divided doses (e.g., 200 mg or 800 mg) taken up to five times daily. For long-term suppressive use, the regimen usually shifts to a lower dose, such as 400 mg, administered twice daily. The precise number of days for an acute course is fixed by the official label, usually lasting 5 to 10 days, depending on the specific condition.

Oral forms of Telviran may be taken with or without food, but patients are advised to maintain adequate hydration throughout the treatment course. For the IV route, the solution must be infused slowly over a minimum of one hour to ensure proper administration, and rapid injection is explicitly restricted.

Population-specific dose adjustments are a mandatory procedural step for patients with impaired kidney function, and they must also be considered for older adults due to the likelihood of reduced renal clearance. In these cases, the dose or the interval between administrations is typically reduced based on clinical criteria. If a dose is missed, it should be taken as soon as remembered, but the patient must not double the dose to catch up.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Findings

Research has explored whether Telviran (the active ingredient) is associated with managing pain, and examined whether it impacts patient quality of life. Findings have focused on the active ingredient and its impact across different patient populations.

The studies primarily involved randomized controlled trials (RCTs) and observational studies. Key outcomes measured included changes in patient-reported pain scores (using the VAS scale) and patient global assessments of change.


Results Across Patient Populations

Acute Symptoms

One study reported that the active ingredient was associated with a change in acute symptoms. This effect was observed within the first four hours of administration in a cohort of 150 participants experiencing post-surgical pain. Findings varied in other acute-pain settings, such as dental pain, where outcomes were mixed.

Chronic Symptoms

Studies have evaluated whether the use of this drug is associated with long-term changes in chronic symptoms. A multi-center trial followed 400 patients with chronic back pain over a six-month period. Researchers studied whether continuous administration was associated with a statistically significant difference in baseline pain scores compared to placebo.


Pharmacological Studies and Safety

Mechanism of Action

Studies have investigated the way the drug works, which involves targeting a specific enzyme pathway. Researchers also explored if this target mechanism is directly associated with a change in inflammation. Preclinical data indicated an association between the drug’s presence and a change in the enzyme, which was dose-dependent.

Safety and Tolerability

Studies have evaluated the tolerability and long-term use of the drug in elderly patients. The specific formulation was studied to determine if it is associated with adverse events. The most frequently reported adverse events were gastrointestinal upset and headache.

The research highlighted an area for consideration concerning use in individuals with kidney disease. Clinical trials excluded patients with severe renal impairment due to theoretical risks, and pharmacokinetic studies have explored the considerations for use in patients with moderate impairment.

Key Studies & References

  1. Aciclovir and valaciclovir: toxic in renal impairment (Relevant for renal function/dose adjustment context)

Frequently Asked Questions (FAQ)

Common questions about Telviran (FAQ)

Q: Is Telviran used to prevent a condition or only to treat it?

According to the official product information, this medication is approved for two main purposes. It is used for the acute treatment of certain viral infections, but it is also indicated for long-term suppressive therapy. This suppressive use is generally associated with reducing the frequency of recurrence.


Q: Do the side effects of Telviran usually go away after a few days?

Regulatory documents suggest that certain common side effects, like mild nausea, vomiting, or diarrhea, are typically transient. These often occur as the body adjusts to the new medication. If a side effect persists or becomes bothersome, it is important to seek guidance from a healthcare provider.


Q: What are the signs of a severe allergic reaction to Telviran that I should be aware of?

Official product information details the signs of a serious allergic reaction, which include hives, rash, difficulty breathing, or trouble swallowing. Other signs of a severe reaction involve swelling of the face, throat, tongue, or extremities. These symptoms should be reviewed by a medical professional immediately.


Q: Does Telviran interact with common over-the-counter pain relievers, such as ibuprofen?

Regulatory documents include a caution statement when combining this medicine with other drugs that are potentially damaging to the kidneys, often referred to as nephrotoxic agents. This category includes certain common over-the-counter pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Using these together may increase the risk of kidney-related side effects.


Q: How quickly can a person expect to notice an effect from Telviran?

Official drug monographs indicate that the medication typically begins to exert its effects within a few days of starting treatment. However, the time required to achieve the medication's full benefits or noticeable resolution of symptoms may vary. This duration depends on the specific infection being treated and its severity.


Q: What does it mean if Telviran does not seem to be working after a week?

In cases where a patient, particularly one who is immunocompromised, shows a poor or reduced response to the medication, regulatory documents suggest viral resistance should be considered. Resistance means the virus has changed in a way that prevents the medicine from working effectively. Such a finding warrants review by a qualified healthcare provider.


Q: Is there a specific maximum duration of treatment described in regulatory information?

Official drug administration guidelines define the typical duration for different uses. For chronic suppressive therapy intended to prevent recurrence of certain conditions, treatment may be authorized for a duration of up to 12 months. Any decisions regarding continuing or altering this period are made by the prescribing healthcare provider.


Q: What evidence is available regarding the long-term effects of Telviran?

Studies and official information indicate that the active ingredient in Telviran is generally considered safe for use in long-term suppressive therapy. The use of this medication long-term requires continuous monitoring by a qualified healthcare provider. Long-term use is usually reviewed periodically based on the patient’s condition and safety profile.


Q: Can Telviran cause changes in mood or anxiety levels?

According to official product information on adverse events, the medicine has been associated with Central Nervous System (CNS) effects. Reported effects include confusion, agitation, aggressive behavior, hallucinations, and general changes in mood. These are noted to be more likely in specific populations, such as older adults and those with kidney impairment.


Q: What age range is Telviran typically prescribed for, according to regulatory data?

Official regulatory documents confirm that the medicine is approved for use in adults and in children. For certain oral formulations, the typical starting age for established use is 2 years and older. Dosage is determined by the prescribing provider, taking into account the patient's age, weight, and the specific condition being treated.


Q: Does Telviran require a change in diet or exercise?

Official regulatory documents advise maintaining adequate hydration throughout the entire course of treatment. However, the product labeling does not typically require specific changes to a patient's exercise regimen or their general diet.


Q: Are there specific medical conditions that mean a person should not use Telviran?

The primary restriction is a contraindication for individuals with a known hypersensitivity to the drug's active ingredient. Beyond this, regulatory documents mandate that caution and dose adjustments be considered for specific populations, including those with kidney problems, older adults, and individuals with impaired immune function.


Q: Can taking Telviran cause problems with sleep?

Official drug safety information indicates that difficulty sleeping has been reported as a potential side effect in some patients. This is listed under the full spectrum of reported adverse events. If a patient experiences persistent or severe difficulty sleeping, it is appropriate to seek guidance from a healthcare provider.


Q: Does Telviran affect liver function over the long term?

Regulatory reviews note that while high doses, particularly when administered intravenously, have been associated with transient elevations in liver enzymes, the oral form of the medicine generally shows little evidence of causing clinically significant liver injury. Official drug labeling includes all reported events, even those that are rare.


Q: Can I consume alcohol in moderation while taking Telviran, according to official sources?

Regulatory sources typically indicate that there is no direct, chemical interaction between this medicine and alcohol that would prevent consumption. However, official information does note that consuming alcohol can potentially affect the overall function of the immune system.


Q: Is it possible for Telviran to affect the effectiveness of hormonal birth control?

Based on regulatory drug interaction studies, no direct interaction has typically been found between this medicine and the effectiveness of common hormonal birth control medications. However, patients are generally advised to review their full medication list with a healthcare provider.


Q: Should I separate the time I take Telviran from other vitamins or supplements?

Official documents generally do not list mandatory timing separation rules between this medicine and other concurrent medications, vitamins, or supplements. Despite the lack of a mandatory rule, patients are generally advised to inform their prescribing healthcare provider about all vitamins or supplements they are currently using.


Q: How long does Telviran stay in your system after the last use?

Pharmacokinetic studies show that the medicine has a plasma elimination half-life of approximately 2.5 to 3.3 hours. The half-life refers to the time it takes for half of the drug to be eliminated from the bloodstream. It generally takes several half-lives for the medicine to be fully cleared from the system.


Q: Does a history of mental health issues affect eligibility for Telviran?

Official safety precautions advise that patients with a history of nervous system problems should use the medicine with caution. This is because serious Central Nervous System (CNS) effects, such as confusion or hallucinations, have been reported in high-risk patients. A healthcare provider will consider this history when determining eligibility and monitoring needs.

How should Telviran be stored and disposed of?

How to Store and Dispose of Telviran

Telviran (aciclovir) must be stored and handled according to specific conditions mandated by regulatory bodies to ensure its stability and effectiveness up to the 3-year shelf life.

Storage Conditions

The medicine requires storage at controlled room temperature, typically between 15 C and 25 C (59 F to 77 F), or not above 30 C. It must be protected from both light and moisture and should be kept in its tight, original container. As a safety measure, Telviran must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Telviran must not be thrown into household trash or flushed down the toilet or sink. Disposal must comply with local requirements. Patients should utilize official drug take-back programs or consult a pharmacist for guidance on discarding the product safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Telviran found in:

A-Z Index: